



WHAT IS CLAIMED IS:

1. A compound of the formula:



wherein X is a linker group having 2-5 functional groups or is absent, n = 1, and Formula II is



wherein R, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent, and wherein K is Arg or an Arg derivative:

R	A -1	B 0	C 1	D 2	E 3	F 4	G 5	H 6	I 7	J 8	K 9
Absent or 3,3DP Aaa Ac	Absent or DmK Lys Lys(εF lu)	Absent or Apc Arg DArg	Absent or ApC Arg DmK	Absent Or MeP Nig NMF	Absent or Hyp Pro	Absent or Ava BALa Dpr	Absent or Add Aud CpG	Absent or Arg Gly Pac	Absent or 2Nal DCpG DF5F	Absent or 2Nal 2Nal- NH ₂	Absent or Arg Arg(H) Arg- CH ₂ O H Arg- NH ₂ Arg(N O ₂) Arg- OMe DArg DArg- NH ₂ DArg(NO ₂)
Aca	NiK	DLys	NiK	Pro		Eac	DDM F	Pac	DIgl	3,4F2 F	Arg- NH ₂
BAPg	PzO	DmK	NiO			Gly	DMF	Ser	DPFF	3Pal	Arg(N O ₂)
Cca		DniK	PaF				Eac	Thr	DPhe	Ac6c	Arg- OMe
Cin Dca		DpaF DPzK	PzO				Igl Lys		DTic Gly	Aic Ana	DArg DArg- NH ₂
Dcg		DPzO					Pac		mABz	Apb	DArg(NO ₂)
Dhq Dmac Dpa		Lys NiK PaF					Phe Thi		pABz Pac PaF(D cg)	Apb Atpc Bip	
F5bz F5c		PzO DArg- (NO ₂)	Arg- (NO ₂)						pAmb	Cmp CpG	
F5pa Gun										DhPhe Dpr(F bz)	
Hxa										Dpr(Pa a)	
Mca Mcg										F5F F5F- NH ₂	


Moti
Pcc
Ppa
Pya

Saa
Ste


Tfmc

Hphe
Ica
Igl
Igl-
NH₂
Ileu
Lys(C
H₃)₃
Lys(F
5bz)
Mapa
MBC
MFF
Nc6G
Nc7G
NMF
OBS
OBT
OBY
OC2Y
Oic
Oic-
NH₂
PABz
Pac
PaF(F
5c)
PaF(F
bz)
PaF(M
cg)
PaF(P
pa)
PaF(Si
n)
pAmb
pAPa
PCF
PdF
PFF
PFF-
NH₂
Phe
PNF
Thi
Tic
Trp
Trx
Tyr

2. A compound of the formula:



wherein X is a linker group having 2-5 functional groups or is absent, $n = 1$, and Formula III is



wherein R, A, B, C, D, E, and F are selected from the following or may be absent, and wherein F is not Arg or an Arg derivative:


R	A	B	C	D	E	F
	1	2	3	4	5	6
Absent or	Absent or	Absent or	Absent or	Absent or	Absent or	Absent or
				or		
2,2Dp	DArg	Arg	Add	2Nal	1Nal	2Nal
3,3Dp	DArg(NO ₂)		Aud	3Pal	2Nal	3Pal
Aaa			Ava	Arg	2Nap	ABza
Ac			Eac	Arg(Tos)	3Pal	ABza
Aca			Lys	Atcp	Apa	Ama
Boc			Pac	D2Nal	Arg	Ampy
Chc				DArg	Arg-NH ₂	Ampz
Cin				DArg(Tos)	Asp	Apa
Ctim				DF5F	Atc	Api
Dca				Dlgl	Atcp	Aptp
Dcg				DPFF	Bip	Aqd
Dhq				Eac	BtA	Aqu
Dmac				F5F	Cys(Meb)	Arg(H)
Dns				Gly	Cys(SO ₃ H)	Arg-CH ₂ OH
Dpa				His	D2Nal	Arg-NH ₂
F5c				Igl	DArg	Arg-OMe
F5pa				mABz	DArg-NH ₂	Asp
F5po				OC2Y	F5F	Asp(Aqu)
Gbc				Pac	Glu	Atcp
Gun				PFF	Gly	Atmp
Hxa					Igl	AtmpO
Mcg					Inp	Atpm
Mse					Iqa	Cyh
Pya					mABz	Dmab
Seb					MC2Y	Dmm
Sin					N-Dmb-Tyr(Bz)-OMe	Dmp
Sul					OC2Y	Dpea

OCiY	Dpma
Oic	Dpr(Dcg-2-Nap)
<i>p</i> ABz	Ecap
PaF(Mes)	F5F-NH ₂
PFF	GaP
Tic	<i>m</i> A ₂ Bz
<i>t</i> Leu	<i>m</i> A ₂ Bz(Dcg)
Trp	<i>m</i> A ₂ Bz(Gun)
Try	<i>m</i> ABz
Try(Bzl)	Mapp
Tyr	Matp
Arg(NO ₂)	MatpO
	<i>p</i> ABz
	PaF
	PaF(Dcg)
	PaF(Mcg)
	PaF-NH ₂
	PFF-NH ₂
	PgF
	PzO
	Sud
	Thm
	Thm
	Tpac
	Tpac
	Tyr(Bz)O
	Me


$$[\text{Formula IV}]_n - \text{X}$$
$$A^0-B^1-C^2-D^3-E^4-F^5-G^6-H^7-I^8-J^9-K^{10}-L^{11}$$

A	B	C	D	E	F	G	H	I	J	K	L
0	1	2	3	4	5	6	7	8	9	10	11
Absent or DArg	Absent or Arg	Absent or Pro	Absent or Lys	Absent or Pro	Absent or DTrp	Absent or Gln	Absent or DTrp	Absent or Phe	Absent or DTrp	Absent or Leu(r)	Absent or Leu-NH ₂ Leu
	DArg					DNM F					

4. A compound of the formula:




wherein X is a linker group having 2-5 functional groups or is absent; n = 1; c indicates cyclization, the site of cyclization selected from the group consisting of the c-terminus, and a side chain functional group; and Formula V is



wherein X, A, B, C, D, E, F, G, H, I, J, and K are selected from the following or may be absent:

X	A	B	C	D	E	F	G	H	I	J	K
	-1	0	1	2	3	4	5	6	7	8	9
Absent or α-Aca 3,3Dp	Absent or Ava BAla DmK Glt Lys Suc	Absent or DArg DNik DPaF DPzK DPzO	Absent or Arg NiK PzO	Absent or Pro	Absent or Hyp	Absent or Gly	Absent or Add Aud Ava BAla DNMF Eac Igl Thi	Absent or DArg Ser Thr	Absent or DDab DDpr DF5F DIgl DLys DOm DPaF Nig Pac Phe	Absent or DTrp F5F Lys Nc7G Oic PaF PFF Phe	Absent or Arg Leu NiK PaF 3Pal

5. A compound of the formula



wherein [ACA] is a compound of claim 1, 2, 3, or 4.

6. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 1, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

7. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 2, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

8. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 3, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

9. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 4, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

10. A method to inhibit tumor growth in an animal in need of such inhibition, comprising administering a compound selected from the group consisting of a compound of claim 5, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg, Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

11. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 1, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg, DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg, DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,

Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

12. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 2,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

13. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 3,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

14. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 4,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.

15. A method to induce apoptosis, comprising administering a compound selected from the group consisting of a compound of claim 5,

DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DIgl-Oic-Arg,
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Nig-Arg,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Oic-Arg,
Lys-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-DTic-ChG,
DArg-Arg-Pro-Hyp-Gly-Igl-Ser-DF5F-Nc7G-Arg, and
DArg-Arg-Pro-Hyp-Gly-Thi-Ser-DTic-Oic-Arg.